Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kestra Medical Technologies (KMTS) EBITDA Margin (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed EBITDA Margin for 2 consecutive years, with 140.72% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1064.0% to 140.72% in Q4 2025 year-over-year; TTM through Oct 2025 was 69.33%, a 8755.0% increase, with the full-year FY2025 number at 47.51%, up 2353.0% from a year prior.
  • EBITDA Margin was 140.72% for Q4 2025 at Kestra Medical Technologies, up from 149.08% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 172.61% in Q2 2025 to a low of 240.98% in Q1 2024.